Bromocriptine: old drug, new formulation and new indication
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Bromocriptine is an ergot alkaloid dopamine D 2 receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of insulin resistance, obesity and diabetes in animals and humans. When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of bromocriptine appears to act centrally to reset circadian rhythms of hypothalamic dopamine and serotonin and improve insulin resistance and other metabolic abnormalities. Phase II and III clinical studies show that QR‐bromocriptine lowers glycated haemoglobin by 0.6–1.2% (7–13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications. Apart from nausea, the drug is well tolerated. The doses used to treat diabetes (up to 4.8 mg daily) are much lower than those used to treat Parkinson's disease and have not been associated with retroperitoneal fibrosis or heart valve abnormalities. QR‐bromocriptine (Cycloset™) has recently been approved in the USA for the treatment of type 2 diabetes mellitus (T2DM). Thus, a QR formulation of bromocriptine timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of hyperglycaemia in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“As evidence accumulates showing the importance of early glycaemic control, earlier and more effective pharmacological intervention is indicated, highlighting the need for additional blood glucose lowering agents, acting through different mechanisms [2].”
BackgroundDecreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats
Obici, S., Feng, Z., Karkanias, G., Baskin, D. G., & Rossetti, L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-861 · Cited by 719
Obici, S., Feng, Z., Arduini, A., Conti, R., & Rossetti, L. (2003) · Nature Medicine · doi:10.1038/nm873 · Cited by 548
Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis
Lam, T. K. T., Pocai, A., Gutierrez-Juarez, R., Obici, S., Bryan, J., Aguilar-Bryan, L., Schwartz, G. J., & Rossetti, L. (2005) · Nature Medicine · doi:10.1038/nm1201 · Cited by 432
Evidence for a circadian rhythm of insulin secretion
Boden, G., Ruiz, J., Urbain, J. L., & Chen, X. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.2.e246 · Cited by 261
Boden, G., Chen, X., & Urbain, J. L. (1996) · Diabetes · doi:10.2337/diab.45.8.1044 · Cited by 228 · cited 1×
“This cyclicity is diminished or lost with persistent insulin resistance in obesity and T2DM and in their first-degree relatives [17,18].”
BackgroundLee, A., Ader, M., Bray, G. A., & Bergman, R. N. (1992) · Diabetes · doi:10.2337/diab.41.6.750 · Cited by 193 · cited 1×
“In lean individuals without diabetes, glucose tolerance is better in the morning and deteriorates by evening, associated with a decrease in insulin sensitivity and a reduction in islet β-cell responsiveness to glucose [16].”
BackgroundDopamine is required for hyperphagia in Lepob/ob mice
Szczypka, M. S., Rainey, M. A., & Palmiter, R. D. (2000) · Nature Genetics · doi:10.1038/75484 · Cited by 134
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Branched-chain amino acids in metabolic signalling and insulin resistance
Lynch, C. J., & Adams, S. H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.171 · Cited by 1,461
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Self-citationPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Self-citation
Metadata
- Authors
- Holt, R. I. G., Barnett, A. H., & Bailey, C. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-10-26
- Volume
- 12
- Issue
- 12
- Pages
- 1048-1057
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2005082727
- Cited by
- 110
- References
- 8
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bromocriptine: old drug, new formulation and new indication. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01304.x
- The paper
- Holt, R. I. G., Barnett, A. H., & Bailey, C. J. (2010). Bromocriptine: old drug, new formulation and new indication. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01304.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.